---
title: 祝贺Alto Neuroscience登陆纽交所
titleEN: Congratulations to Alto Neuroscience Listed on the NYSE
hide: false
type: 医疗健康
typeEN: Healthcare
createDate: 2024-02-02T09:33:35.144Z
abstract: 2024年2月2日，精神领域精准药物研发公司Alto
  Neuroscience（以下简称“Alto”）成功登陆纽交所，股票代码为“ANRO”。此次Alto上市发行价为16美元/股，募集资金超1.29亿美元。高榕资本于2023年参与投资了Alto的C轮融资。
abstractEN: Alto Neuroscience is a clinical-stage biopharmaceutical company with
  a mission to redefine psychiatry by leveraging neurobiology to develop
  personalized and highly effective treatment options.
content: >-
  2024年2月2日，精神领域精准药物研发公司Alto
  Neuroscience（以下简称“Alto”）成功登陆纽交所，股票代码为“ANRO”。此次Alto上市发行价为16美元/股，募集资金超1.29亿美元。高榕资本于2023年参与投资了Alto的C轮融资。


  Alto是一家临床阶段的生物制药公司，致力于通过精神疾病领域的大数据分析，为精神疾病患者开发个性化和高效的治疗药物，重新定义精神疾病疗法。


  ![](/static/img/alto-neuroscience.png)


  **开发差异化药物研发路径**


  **提高精神疾病药物研发成功率**


  Alto由斯坦福大学精神病学教授Amit Etkin博士于2019年创立，旨在基于对脑功能的深度理解，通过差异化的药物研发路径，更高效地为精神疾病患者开发具有精准疗效的药物，避免可能漫长且无效的治疗过程。


  由于缺少药物对人脑影响的了解，传统的精神疾病药物开发经常在临床阶段面临高失败率。而Alto已建立起精神疾病精准药物研发平台，通过认知检测、脑电、可穿戴设备等方法采集数据，并结合严格的数据分析，提炼出大脑的生物标志特征，随后基于这些特征去识别和筛选对候选治疗药物显示出更好临床反应的患者。Alto的方法有望颠覆精神疾病药物研发的方式，提升药物临床成功的可能性。


  **面向巨大精神健康需求**


  **快速推进临床管线进程**


  精神健康状况越来越受到全球关注。按目前估算，超过50%的美国人口在其一生中会被诊断患有精神疾病，2020年美国在精神健康服务方面的花费约为2800亿美元。而现有疗法的局限性是导致成本上升的主要原因，因为这些疗法往往对于很大一部分患者无效。尽管个性化疗法已经在诸如肿瘤治疗等领域取得显著进展，但精神领域药物研发和疗法很大程度上仍然不具备个体针对性。


  目前Alto已推进开发5条临床阶段的管线，初期面向以特定大脑生物标志物为特征的重度抑郁症（MDD）和精神分裂症人群。上述管线均至少通过临床I期试验验证，并观察到良好的安全性和耐受性。Alto进展最快的两款候选药物——ALTO-100和ALTO-300已分别针对超过200名患者成功完成临床Ⅱa期试验，并快速推进到临床Ⅱb期。其中ALTO-100用于治疗以神经认知生物标志物为特征的MDD患者；ALTO-300则用于治疗以脑电生物标志物为特征的MDD患者。此外，Alto也计划在2024上半年启动ALTO-101和ALTO-203的Ⅱ期疗效验证临床试验，分别用于治疗有认知障碍的精神分裂症患者，以及具有快感缺失的MDD患者。


  ![](/static/img/alto-pipeline.jpg)


  高榕资本董事总经理于江涛博士表示，“精神疾病在全球范围愈发受到重视，而这一领域的药物研发模式亟待突破。Amit Etkin教授过往在斯坦福大学潜心研究十多年，受益于来自肿瘤等其他领域的经验，Etkin教授通过测试不同病人对于药物的反应寻找生物标志物，并通过该标志物分类病人，建立其与药物疗效的对应关系。通过这样的生物标志物来筛选病人入组，能够提高临床的成功概率，甚至能使之前面临临床失败的药物起死回生，从而实现精神疾病的精准治疗。我们期待Alto早日推进创新药物问世、造福精神疾病患者。”


  在医疗健康领域，高榕希望找到和陪伴真正具有国际创新能力的公司，并持续投资新药研发、医疗器械、数字健康与医疗服务等方向的优秀企业。


  ![](/static/img/alto祝贺海报.png)
contentEN: >-
  On February 2, 2024, Alto Neuroscience, a precision medicine company focused
  on the mental health sector, has successfully debuted on the New York Stock
  Exchange (NYSE) under the ticker symbol "ANRO." The IPO was priced at $16 per
  share, raising over $129 million in funds. Notably, in 2023, Alto received
  investment from Gaorong Ventures during its Series C financing round.


  Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.


  ![](/static/img/alto-neuroscience.png)


  Founded in 2019 by Dr. Amit Etkin, a psychiatry professor at Stanford University, Alto leverages a profound understanding of brain functionality. By adopting a differentiated drug development approach, Alto aims to efficiently create precision drugs for mental health patients, avoiding potentially lengthy and ineffective treatment processes. Traditional psychiatric drug development often faces high failure rates at the clinical stage due to a lack of understanding of how drugs affect the human brain.


  Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates.


  Currently, Alto has progressed five clinical-stage pipelines targeting populations with specific brain biomarkers associated with MDD and schizophrenia. These pipelines have undergone at least Phase I clinical trials, demonstrating good safety and tolerability. The fastest advancing candidates, ALTO-100 and ALTO-300, have successfully completed Phase IIa trials with over 200 patients each and are swiftly progressing to Phase IIb. ALTO-100 targets MDD patients with neural cognitive biomarkers, while ALTO-300 targets MDD patients with EEG biomarkers. Furthermore, Alto plans to initiate Phase II efficacy validation clinical trials for ALTO-101 and ALTO-203 in the first half of 2024. These trials will respectively focus on treating schizophrenic patients with cognitive impairments and MDD patients experiencing pleasure loss.


  In the healthcare sector, Gaorong Ventures seeks to identify and support internationally innovative companies, continuing its investment in outstanding enterprises across new drug development, medical devices, digital health, and medical services.
pic: /static/img/alto-neuroscience.png
highLight: false
---
